1 Stock Down 43% to Buy and Hold for 10 Years

The pandemic has receded substantially, and with it, the need for vaccines and medicines against COVID-19. That's not to say we no longer need them -- just a lot less so than we did in the earlier years of the outbreak.Biotech giant Moderna (MRNA 0.64%) rose to prominence and made a lot of money thanks to its marketing of one of the leading COVID-19 vaccines, but last year, the company's shares dropped like a rock along with its revenue and earnings. Still, there is a lot to like about Moderna's business.Le ...